Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with 11% revenue growth and improved EBITDA margins. The company raised revenue and EBITDA guidance, indicating confidence in future performance. New product launches and cost optimization efforts are positive signals. Despite competitive pressures and supply chain challenges, the company's operational efficiency and break-even free cash flow are promising. The Q&A section shows positive analyst sentiment, with increased Cologuard orders and strategic investments. Although some uncertainties exist, the overall outlook suggests a positive stock price movement.
Key Financial Performance
Total Revenue $540 million, an increase of 11% year-over-year, driven by broad-based Cologuard growth, particularly in rescreens and care gap programs.
Screening Revenue $540 million, up 14% year-over-year, exceeding guidance due to continued success in rescreens and growth in new ordering providers.
Precision Oncology Revenue $167 million, an increase of 4% year-over-year, driven by strength in Oncotype DX adoption internationally.
Adjusted EBITDA $63 million, an increase of 61% year-over-year, with margin expansion of 280 basis points due to volume leverage, productivity, and cost-cutting initiatives.
Adjusted G&A Decreased by 7% year-over-year, improving more than 520 basis points as a percentage of revenue, partially offset by increased sales and marketing investments.
Free Cash Flow Reached break even, a year-over-year improvement of $120 million, driven by productivity and working capital initiatives.
Cash and Securities $786 million, reflecting a $249 million convertible note paydown.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Launched Cologuard Plus, a next-generation colorectal cancer screening test with Medicare coverage and quality measure inclusion. Launched Oncodetect, a molecular residual disease test aimed at benefiting 6 million cancer patients.
Upcoming Product Launches: Cancerguard, a multi-cancer screening test, is set to launch in the second half of 2025.
Market Expansion: Engaging providers with the highest potential to order at record rates, expanding the number of providers engaged each quarter. Customer initiated ordering platform grew triple digits in Q1 2025.
Operational Efficiencies: Took $25 million in actions to optimize costs, expecting annual savings of $18 million. Adjusted G&A improved more than 520 basis points and was down 7% year-over-year.
Strategic Shifts: Shifted to a purpose-built commercial organization and expanded field team to enhance provider engagement. Focus on increasing adherence in care gap programs, which grew triple digits last year.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: Exact Sciences is actively working with Medicare to secure reimbursement for their new test, Oncodetect, in colorectal cancer, which is expected to occur this quarter.
Competitive Pressures: The company faces competitive pressures in the market for cancer screening tests, particularly with the launch of Cologuard Plus, which aims to establish itself as a first option in healthcare provider screening toolkits.
Supply Chain Challenges: There is a potential risk related to the launch of Cologuard Plus, which may temporarily impact cash flow due to an expected build in accounts receivable.
Economic Factors: The company navigated through one of the worst flu seasons in years, which could have impacted their operations and revenue.
Operational Efficiency: While the company has taken actions to optimize costs and increase operational efficiency, there is an ongoing challenge to maintain this momentum and ensure that these initiatives deliver the expected savings.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cologuard Plus Launch: Launched Cologuard Plus, a next-generation colorectal cancer screening test with Medicare coverage and quality measure inclusion.
Oncodetect Launch: Launched Oncodetect, a molecular residual disease test aimed at benefiting 6 million cancer patients.
Commercial Initiatives: Expanded commercial organization and field team to engage high-potential providers, resulting in increased customer engagement and satisfaction.
Care Gap Program: Grew care gap program triple digits last year, with expectations for strong double-digit growth this year.
Customer Initiated Ordering Platform: Grew triple digits in the first quarter, with plans for further improvements.
Cancerguard Launch: On track for the launch of Cancerguard in the second half of 2025.
Total Revenue Guidance: Increased total revenue guidance to between $3.07 billion and $3.12 billion for the year.
Screening Revenue Guidance: Expect screening revenue between $595 million and $605 million for Q2 and between $2.39 billion and $2.425 billion for the full year.
Precision Oncology Revenue Guidance: Expect precision oncology revenue between $170 million and $175 million for Q2 and between $680 million and $695 million for the full year.
Adjusted EBITDA Guidance: Raised adjusted EBITDA guidance to between $425 million and $455 million for the full year, implying 14.2% adjusted EBITDA margins at midpoint.
Free Cash Flow Expectations: Expect strong full-year cash generation with meaningful growth in free cash flow.
Cost Optimization Actions: Took $25 million in actions to optimize costs, expecting annual savings of $18 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Free Cash Flow: Free cash flow reached break even during the first quarter, a year-over-year improvement of $120 million.
Cash and Securities: We ended the quarter with cash and securities of $786 million, which reflects the $249 million convertible note paydown.
Annual Savings from Cost Optimization: We expect these actions to deliver annual savings of $18 million with $9 million coming in 2025.
Revenue Guidance: We are increasing total revenue guidance to between $3.07 and $3.12 billion for the year, an increase of $40 million at midpoint.
Adjusted EBITDA Guidance: We are raising adjusted EBITDA guidance to between $425 million to $455 million for the full year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are some of the changes made on the commercial front that are driving new Cologuard orders?
A:We have made several changes including shifting to territories, dynamic calling lists, and increasing the volume of Doc calls. Our rep productivity is up about 10%, and we are engaging with the right customers with the right frequency.
Q:Can you clarify the 30% year-over-year increase in customer engagement? Is that Doc calls or Doc calls per rep?
A:It's Doc calls. The volume of calls is up.
Q:Can you unpack guidance a bit? How should we think about cadence in the back half of the year?
A:It's early in the year, and we treat any increase in guidance with caution. However, we have excellent visibility into Q2 shaping up in terms of orders.
Q:Can you unpack where you made investments in the first quarter? Was there anything one-time in there?
A:Sales and marketing was higher than modeled due to investments in our screening portfolio and supporting new product launches.
Q:What is the current contribution of rescreens to total Cologuard orders?
A:Rescreens are about 25% of total Cologuard orders.
Q:What are the hurdles left for the blood testing timeline?
A:We are on track from a timing standpoint, but there are many operational preparations needed. The quality measures are gated by USPSTF, which may take a few years.
Q:Can you provide a view on the traction of Cologuard Plus?
A:Cologuard Plus is currently available for Medicare Part B patients, which is about 14-15% of our customer volume.
Q:What is the pricing for Cancer Guard?
A:We have not decided yet on the pricing.
Q:What is the expected gross margin progression throughout the year?
A:We expect to sustain or improve gross margins as we launch Cologuard Plus.
Q:What is the company's approach to capital allocation as free cash flow improves?
A:We are focused on organic investments but will also consider acquisitions as we improve our financial profile.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific timeline for blood testing and the pricing for Cancer Guard, stating that they have not decided yet.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bernstein
Chairman
Chief Financial
Financial Officer
GA
Investor Relations
Precision Oncology
President Investor
Research
Vice President
action
adoption
afternoon result
care gap
cash flow
conference today
core
customer
expectation
figure
gap program
improvement
increase
investment
leverage
market
midpoint
mission
news release
provider potential
rescreens care
statement
success
website
EXAS Transcript
Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reflects strong financial performance with raised revenue and EBITDA guidance, a solid productivity plan, and promising product developments like Cologuard Plus and Cancerguard. The Q&A section highlights ongoing payer negotiations and future growth potential, despite some uncertainties in timelines and pricing strategies. The overall sentiment is positive, supported by optimistic guidance and strategic initiatives aimed at long-term growth.
Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)
Neutral9-9
Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral9-3
EXAS Slides
EXAS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
